Vinay Prasad’s short yet two-act tenure at the FDA was wild. How does anyone follow him as the new leader of biologics oversight at the agency?
Someone I know at the FDA joked to me recently that I should be the new director of the Center for Biologics Evaluation and Research (CBER) after Prasad. I literally laughed out loud at how comical that sounded, but it got me thinking: Who would be both willing to do it and could get picked?
Further, what’s awaiting them? Prasad became a favorite punching bag of many, including the Wall Street Journal editorial board and right-wing activists like Laura Loomer .
They are teed up to clobber the next person, too. Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 13 Apr 2026.
The item focuses on Opinion: STAT+: Landmines await Vinay Prasad’s successor at the FDA.
Review the original article for the full source wording and details.